Phase II Pilot Trial of an Indoleamine 2, 3,diosygenase -1 ( IDO1) Inhibitor (INCBO24360) Plus a Multipeptide Melanoma Vaccine ( MELTAC 12.1 ) in Patients with Advanced Melanoma

Administered By

Contributors

Start/End

  • September 1, 2015 - August 31, 2017